Capricor Therapeutics Inc. Insider Trading

CAPR

Last 12 months

Insiders sold $8.37M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Oct 2023.

Net open-market

−$8.37M

0 buys · 10 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Oct 2023

Oct 12, 2023

Get an email when CAPR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 25	Anthony Bergmann Chief Financial Officer	Sold10b5-1 plan	24,100	$30.38	732K	68%	Form 4
Jun 25	Karen Krasney EVP, General Counsel	Sold10b5-1 plan	24,100	$30.38	732K	44%	Form 4
Jun 22 – 24	Anthony Bergmann Chief Financial Officer	Sold10b5-1 plan 2 parts	900	$30.00 average	27K	7.4%	Form 4
Jun 22 – 24	Karen Krasney EVP, General Counsel	Sold10b5-1 plan 2 parts	900	$30.00 average	27K	2.9%	Form 4
May 1	Anthony Bergmann Chief Financial Officer	Sold10b5-1 plan	25,000	$31.70	793K	75%	Form 4
May 1	Karen Krasney EVP, General Counsel	Sold10b5-1 plan	25,000	$31.70	793K	45%	Form 4
Apr 2	Karimah Es Sabar Director	Sold10b5-1 plan	7,529	$32.00	241K	100%	Form 4
Mar 31 – Apr 1	Karimah Es Sabar Director	Sold10b5-1 plan 2 parts	115,000	$30.57 average	$3.52M	100%	Form 4
Mar 31	Anthony Bergmann Chief Financial Officer	Sold10b5-1 plan	25,000	$30.13	753K	75%	Form 4
Mar 31	Karen Krasney EVP, General Counsel	Sold10b5-1 plan	25,000	$30.12	753K	45%	Form 4

Jun 2510b5-1 plan
Anthony Bergmann
Chief Financial Officer · sold 24,100 at $30.38
732K
68% of stake
Jun 2510b5-1 plan
Karen Krasney
EVP, General Counsel · sold 24,100 at $30.38
732K
44% of stake
Jun 22 – 2410b5-1 plan
Anthony Bergmann
Chief Financial Officer · sold 900 at avg $30.00
27K
7.4% of stake
Jun 22 – 2410b5-1 plan
Karen Krasney
EVP, General Counsel · sold 900 at avg $30.00
27K
2.9% of stake
May 110b5-1 plan
Anthony Bergmann
Chief Financial Officer · sold 25,000 at $31.70
793K
75% of stake
May 110b5-1 plan
Karen Krasney
EVP, General Counsel · sold 25,000 at $31.70
793K
45% of stake
Apr 210b5-1 plan
Karimah Es Sabar
Director · sold 7,529 at $32.00
241K
100% of stake
Mar 31 – Apr 110b5-1 plan
Karimah Es Sabar
Director · sold 115,000 at avg $30.57
$3.52M
100% of stake
Mar 3110b5-1 plan
Anthony Bergmann
Chief Financial Officer · sold 25,000 at $30.13
753K
75% of stake
Mar 3110b5-1 plan
Karen Krasney
EVP, General Counsel · sold 25,000 at $30.12
753K
45% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CAPR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CAPR

CompareIntrinsic value

PRLDPrelude Therapeutics Incorporated

$4.08+7.94%40

JANXJanux Therapeutics Inc.

$18.18+2.02%40

BGMBGM Group Ltd.

$8.81-7.65%26

SLGLSol-Gel Technologies Ltd.

$66.00+3.43%65

SCYXScynexis, Inc.

$3.84-2.54%40

CELUCelularity Inc.

$0.81-1.00%0

CTMXCytomX Therapeutics Inc.

$2.35+7.80%10

QUREuniQure N.V.

$23.07-3.35%10

Held by ETFs

CAPR is in 16 US ETFs. The largest of them, with CAPR's weight in each:

Spot a number that looks wrong? Check it in CAPR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CAPR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.